Punganuru, S.R.; Arutla, V.; Zhao, W.; Rajaei, M.; Deokar, H.; Zhang, R.; Buolamwini, J.K.; Srivenugopal, K.S.; Wang, W.
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells 2020, 9, 1592.
https://doi.org/10.3390/cells9071592
AMA Style
Punganuru SR, Arutla V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W.
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020; 9(7):1592.
https://doi.org/10.3390/cells9071592
Chicago/Turabian Style
Punganuru, Surendra R., Viswanath Arutla, Wei Zhao, Mehrdad Rajaei, Hemantkumar Deokar, Ruiwen Zhang, John K. Buolamwini, Kalkunte S. Srivenugopal, and Wei Wang.
2020. "Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action" Cells 9, no. 7: 1592.
https://doi.org/10.3390/cells9071592
APA Style
Punganuru, S. R., Arutla, V., Zhao, W., Rajaei, M., Deokar, H., Zhang, R., Buolamwini, J. K., Srivenugopal, K. S., & Wang, W.
(2020). Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells, 9(7), 1592.
https://doi.org/10.3390/cells9071592